Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of immunotherapy in combination with epigenetic therapy in an esophageal adenocarcinoma model.
Authors
Ashten Omstead
Esophageal and Lung Research, Allegheny Health Network, Pittsburgh, PA
Ashten Omstead , Ping Zheng , Michael Paskewicz , Anastasia Gorbunova , Madison Salvitti , Juliann E. Kosovec , Blair A. Jobe , Ronan Joseph Kelly , Ali Hussainy Zaidi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.335
Abstract #
335
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Potency of CD8+ T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model.
First Author: Laila Babar
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
First Author: Rui-Hua Xu
Poster
2022 ASCO Annual Meeting
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
First Author: Snehal Patel
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
First Author: Ariela Noy